Eli Lilly Stock Surges on Demand for Weight-Loss Drugs
Eli Lilly beat earnings expectations for the first quarter and raised its outlook for the year.
Eli Lilly (LLY) stock is rallying more than 5% in Thursday's session after the pharmaceutical giant reported strong first-quarter earnings results and raised its full-year outlook.
In the three months ended March 31, Eli Lilly's revenue increased 26% from the year-ago period to $8.8 billion. Earnings per share (EPS) surged 59.3% to $2.58.
"Lilly's first-quarter performance reflects solid year-over-year revenue growth with strong sales of [weight-loss drugs] Mounjaro and Zepbound," Eli Lilly CEO David A. Ricks said in a statement. "Our progress in addressing some of the world's most significant healthcare challenges has resulted in increased demand for our medicines."
Sign up for Kiplinger’s Free E-Newsletters
Profit and prosper with the best of expert advice on investing, taxes, retirement, personal finance and more - straight to your e-mail.
Profit and prosper with the best of expert advice - straight to your e-mail.
The Q1 results were mixed compared with analysts' expectations, which called for revenue of $8.9 billion and EPS of $2.46, according to Yahoo Finance.
Still, Eli Lilly's weaker-than-expected revenue was quickly overlooked after the company increased its full-year outlook. The drugmaker now expects full-year revenue in the range of $42.4 billion to $43.6 billion and earnings to arrive between $13.50 to $14.00 per share. This is up from LLY's previous outlook for revenue in the range of $40.4 billion to $41.6 billion and earnings of $12.20 to $12.70 per share.
"As we continue to make pipeline investments that position us for future growth, we are rapidly expanding manufacturing capacity to make our incretin medicines available to more patients," Ricks said.
Where does Eli Lilly stock stand with analysts?
Analysts were already bullish on the healthcare stock ahead of earnings. According to S&P Global Market Intelligence, the consensus analyst target price for LLY shares is $813.32, representing an upside of just over 5% to current levels. Meanwhile, the consensus recommendation is a Buy.
However, Damien Conover, director of equity strategy at Morningstar, believes Eli Lilly stock was running a little hot ahead of earnings.
"With its 2-star rating, we believe Eli Lilly's stock is overvalued compared with our long-term fair value estimate of $500," Conover said. The $500 estimate represents a downside of more than 35% to current levels.
Related Content
To continue reading this article
please register for free
This is different from signing in to your print subscription
Why am I seeing this? Find out more here
Joey Solitro is a freelance financial journalist at Kiplinger with more than a decade of experience. A longtime equity analyst, Joey has covered a range of industries for media outlets including The Motley Fool, Seeking Alpha, Market Realist, and TipRanks. Joey holds a bachelor's degree in business administration.
-
10 Things You Should Know About Estate Planning for Singles
A guide to how to navigate estate planning as a single person.
By David Rodeck Published
-
Future U.S. Economic Growth Hinges on Immigrants
The Kiplinger Letter With the native birthrate slipping, employers are increasingly relying on foreign-born workers to staff up.
By David Payne Published
-
Stock Market Today: Nasdaq Hits New High Ahead of Nvidia Earnings
Nvidia is a critical player in the AI space and its quarterly earnings report is a key event on Wall Street this week.
By Karee Venema Published
-
Dow 40,000: What the Experts Are Saying
The pros weigh in on the implications of the Dow topping 40K for the first time ever.
By Dan Burrows Published
-
Does Activist Investing Work? These Success Stories Say Yes
Activist investors take stakes in companies to boost shareholder value. While not always successful, these five examples show activist investing can work.
By Will Ashworth Published
-
Stock Market Today: Dow Nabs First-Ever Close Above 40,000
Robinhood stock popped after a double-upgrade from BofA Securities, while Reddit jumped on a new OpenAI deal.
By Karee Venema Published
-
Take-Two Interactive Delays GTA 6 Release: What To Know
Take-Two Interactive stock is higher even after the video-game maker delayed the release of Grand Theft Auto VI. Here's what you need to know.
By Joey Solitro Published
-
Reddit Stock Surges on OpenAI Deal: What You Need To Know
Reddit inked a partnership with OpenAI that will bring new artificial intelligence features to the social media platform.
By Joey Solitro Published
-
Stock Market Today: Dow Flirts With 40K After Walmart Earnings
The 30-stock index briefly traded above the 40,000 mark as blue chip retail stock Walmart surged after earnings.
By Karee Venema Published
-
Cisco Stock Struggles Despite Earnings Beat, Strong Outlook
Cisco stock is lower Thursday even after the tech giant's beat-and-raise quarter. Here's what you need to know.
By Joey Solitro Published